New Path Molecular

We use synthetic versions of defensins to target our conjugates to cancer cells. Defensins are naturally evolved small proteins that form part of the innate immune system. We have developed analogues that bind selectively to phosphatidylserine, a non-gene templated biomarker of cancer which is genetic alteration agnostic and an immune checkpoint.

New Path has developed novel linker chemistry to ensure the payload is released in the tumour microenviroment without the need for endocytosis

Our synthetic chemistry allows us to modify validated payloads so that on release in the tumour microenviroment they are highly cell penetrant